HSP Share Price

Open 89.96 Change Price %
High 89.98 1 Day -0.01 -0.01
Low 89.95 1 Week 0.00 0.00
Close 89.95 1 Month 0.00 0.00
Volume 13143972 1 Year 0.00 0.00
52 Week High 15.25
52 Week Low 3.55
HSP Important Levels
Resistance 2 89.98
Resistance 1 89.97
Pivot 89.96
Support 1 89.93
Support 2 89.92
NYSE USA Most Active Stocks
BAC 23.09 0.61%
BAC 23.09 0.61%
BAC 23.09 0.61%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
AMD 10.34 0.00%
More..
NYSE USA Top Gainers Stocks
INVN 10.55 27.57%
POM 26.93 26.79%
POM 26.93 26.79%
EBS 32.37 18.92%
EBS 32.37 18.92%
SWC 17.32 17.98%
SWC 17.32 17.98%
PACD 5.33 17.40%
SDLP 4.48 16.06%
UTI 3.55 14.15%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Hospira Inc (NYSE: HSP)

HSP Technical Analysis 5
As on 2nd Sep 2015 HSP Share Price closed @ 89.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 76.64 & Strong Buy for SHORT-TERM with Stoploss of 89.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
HSP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
HSP Other Details
Segment EQ
Market Capital 5045836288.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.hospira.com
HSP Address
HSP
275 North Field Drive
Lake Forest, IL 60045
United States
Phone: 224-212-2000
HSP Latest News
ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer ...   GlobeNewswire (press release)   - 06th Oct 16
Medicines Company v. Hospira, Inc   Lexology (registration)   - 29th Aug 16
The Medicines Company v. Hospira, Inc. (Fed. Cir. 2016) (en banc)   JD Supra (press release)   - 14th Jul 16
Hospira, Amgen Duel Over Biosimilar Ruling's Impact   Law360 (subscription)   - 08th Jul 16
Hospira To Fed. Circ.: Don't Alter On-Sale Rule For Patents   Law360 (subscription)   - 06th May 16
Hospira Can't Shake Patent Row Over Generic Aloxi   Law360 (subscription)   - 06th Apr 16
Hospira Urges Fed. Circ. To Keep On-Sale Bar For Patents   Law360 (subscription)   - 16th Mar 16
Cubist Pharmaceuticals, Inc. v. Hospira, Inc., Inc., Nos. 2015-1197, 2015-1204 ...   American University Intellectual Property Brief   - 03rd Feb 16
Pfizer Said to Weigh Sale of Pump Unit Acquired in Hospira Deal   Bloomberg   - 14th Jan 16
Pfizer to Buy Hospira for $16 Billion   Wall Street Journal   - 05th Feb 15
Interactive Technical Analysis Chart Hospira Inc ( HSP NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hospira Inc
HSP Business Profile
Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.